Celyad Oncology SA
CLYYF
$0.65
-$0.03-4.41%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -1.48M | -1.53M | -1.64M | -1.65M | -2.53M |
| Total Depreciation and Amortization | 72.50K | 74.80K | 123.20K | 124.30K | 175.50K |
| Total Amortization of Deferred Charges | 45.30K | 46.70K | -- | -- | 38.20K |
| Total Other Non-Cash Items | -89.50K | -92.30K | 21.00K | 21.20K | 182.50K |
| Change in Net Operating Assets | -65.00K | -67.10K | -29.60K | -29.90K | -1.56M |
| Cash from Operations | -1.52M | -1.57M | -1.52M | -1.54M | -3.70M |
| Capital Expenditure | -- | -- | -- | -- | -313.80K |
| Sale of Property, Plant, and Equipment | 8.00K | 8.20K | -- | -- | 14.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.00 | 0.00 | -63.50K | -64.00K | -500.00 |
| Cash from Investing | 8.00K | 8.20K | -63.50K | -64.00K | -300.40K |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -42.00K | -42.00K | -41.50K | -41.50K | -26.50K |
| Issuance of Common Stock | -- | -- | -- | -- | 4.75M |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 446.00K | 446.00K | 1.13M | 1.13M | 10.00K |
| Cash from Financing | 430.70K | 444.10K | 1.17M | 1.18M | 5.09M |
| Foreign Exchange rate Adjustments | -2.10K | -2.20K | -- | -- | 0.00 |
| Miscellaneous Cash Flow Adjustments | 500.00 | 600.00 | -500.00 | -500.00 | -- |
| Net Change in Cash | -1.08M | -1.12M | -417.10K | -420.70K | 1.09M |